Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Added a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T05:51:27.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0, indicating a newer release.
    Difference
    0.1%
    Check dated 2025-09-29T03:11:43.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:58:12.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T16:55:01.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated to include a new facility name and location, along with a detailed publication related to Hodgkin lymphoma, while several terms and references related to previous content have been removed.
    Difference
    7%
    Check dated 2025-08-31T12:07:57.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-17T04:35:06.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.